Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PHIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.84M
- EPS (TTM)
- -$1.21
- Dividend yield
- None
- 52-week range
- 0.6395 – 1.88
- Day range
- 0.6395 – 0.7308
- Volume / Avg
- 145.41K / 106.09K
- Beta
- —
- Shares outstanding
- 11.95M
52-week range
PHIO stock today
On Nov 20, PHIO ended the session at $0.656, shedding $0.059 (8.25%), versus the S&P 500's 3.70% decline. At this level, PHIO sits near the bottom of its 52-week range of $0.6395 to $1.88: 65.1% below the high, set on Feb 13, 2026 and 2.6% above the low. PHIO is down 37.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 41.4%.
Phio Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.21), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Phio Pharmaceuticals
Company profilePhio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert J. Bitterman
- Headquarters
- King of Prussia, PA
- Employees
- 6
- Website
- phiopharma.com
Financial highlights
Full financialsPhio Pharmaceuticals reported a net loss of $8.7 million, compared with a loss of $7.2 million a year earlier.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-8.70M | $-7.15M | $-10.83M | $-11.48M | $-13.29M |
| EPS (diluted) | — | $-9.08 | $-46.76 | $-10.10 | $-12.43 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$14.00+2034.15%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.36 vs $-0.36
- Surprise
- 0.00%
PHIO news
All PHIO newsPhio Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CLRBCellectar Biosciences Inc. | 0.797 | -11.50% | $8.00M | vs PHIO |
| DAREDare Bioscience Inc. | 0.4074 | -9.87% | $8.01M | vs PHIO |
| VTGNVistagen Therapeutics Inc. | 0.1636 | -12.33% | $7.56M | vs PHIO |
| PTNPalatin Technologies Inc. | 4.58 | -7.10% | $8.16M | vs PHIO |
| MBRXMoleculin Biotech Inc. | 7.74 | -2.40% | $8.22M | vs PHIO |
| RKTORocket One Inc. | 0.297 | +5.24% | $7.39M | vs PHIO |
| QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | 1.29 | -9.15% | $8.29M | vs PHIO |
| IMRNImmuron Limited ADR | 0.8998 | +5.80% | $7.26M | vs PHIO |
Indexes, lists and sector
Phio Pharmaceuticals stock FAQ
What is Phio Pharmaceuticals's stock price today?
PHIO last traded at $0.656 as of Nov 20, 4:00 PM EST, down 8.25% on the day. Prices are delayed at least 15 minutes.
Does Phio Pharmaceuticals pay a dividend?
No. Phio Pharmaceuticals does not currently pay a regular cash dividend.
Who is Phio Pharmaceuticals's CEO?
Mr. Robert J. Bitterman is the chief executive officer of Phio Pharmaceuticals Corp., which has about 6 employees.
Has PHIO ever split its stock?
Yes. The most recent PHIO stock split was a 1-for-9 split on Jul 5, 2024, one of 6 splits on record.
What is the PHIO 52-week high?
The 52-week high for PHIO is $1.88 and the 52-week low is $0.6395. The stock is currently 65.1% below its high.